EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MAP4K2 suppresses antitumor immunity in a pancreatic cancer model by promoting Treg differentiation

Huai-Chia Chuang, Chia-Wen Wang, Chia-Hsin Hsueh, Yu-Zhi Xiao, Ching-Yi Tsai, Pu-Ming Hsu, Evelyn L Tan, Hsien-Yi Chiu, Tse-Hua Tan

Journal of Clinical Investigation · 16.03.2026 · 136 (6)

DOI: 10.1172/jci196379 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 29.01.2026. Verfasst von Huai-Chia Chuang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Research Center, National Health Research Institutes, Zhunan, Taiwan. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Pancreatic Neoplasms, Protein Serine-Threonine Kinases, Cell Differentiation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health Research Institutes (NHRI), Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

MAP kinase kinase kinase kinase (MAP4K) family kinases are key kinases for T cell–mediated immune responses; however, in vivo roles of MAP4K2 in immune regulation remain unclear. Using T cell–specific Map4k2 conditional knockout (T- Map4k2 cKO) mice, scRNA-seq, and mass spectrometry analysis, we found that MAP4K2 interacted with DDX39B, induced forkhead box protein P3 (FOXP3) gene expression, and promoted Treg differentiation. Mechanistically, MAP4K2 directly phosphorylated the DEAD box protein DDX39B, leading to DDX39B nuclear translocation and subsequent Foxp3 RNA splicing. MAP4K2-induced FOXP3 mRNA levels were abolished in DDX39B knockout T cells. Furthermore, T- Map4k2 cKO mice displayed the reduction of Treg population and the sustained inflammation during remission phase of EAE autoimmune disease model. Remarkably, the anti–PD-1 immunotherapeutic effect on pancreatic cancer was significantly improved in T- Map4k2 cKO mice, Treg-specific Map4k2 -deficient mice, adoptively transferred chimeric mice, or MAP4K2-inhibitor–treated mice. Consistently, scRNA-seq analysis of patients with pancreatic cancer showed increased MAP4K2 levels in infiltrating Treg cells. Collectively, MAP4K2 promotes Treg differentiation by inducing DDX39B nuclear translocation, leading to the attenuation of antitumor immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-Lymphocytes, RegulatoryPancreatic NeoplasmsProtein Serine-Threonine KinasesCell DifferentiationNeoplasm ProteinsAnimalsMiceMice, KnockoutHumansForkhead Transcription FactorsDEAD-box RNA HelicasesDisease Models, Animal

Stichwörter der Autor:innen

Cell biologyImmunologyOncologyProtein kinasesSignal transductionTregs

Substanzen

Protein Serine-Threonine KinasesForkhead Transcription FactorsDEAD-box RNA HelicasesFoxp3 protein, mouseNeoplasm Proteins

Autor:innen und Institutionen

  • Immunology Research Center, National Health Research Institutes, Zhunan, Taiwan.
  • Department of Dermatology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan.

Förderung

  • National Health Research Institutes (NHRI), Taiwan

Zitieren

APA

Chuang, H. C., Wang, C. W., Hsueh, C. H., Xiao, Y. Z., Tsai, C. Y., Hsu, P. M., Tan, E. L., Chiu, H. Y., & Tan, T. H. (2026). MAP4K2 suppresses antitumor immunity in a pancreatic cancer model by promoting Treg differentiation. Journal of Clinical Investigation, 136(6). https://doi.org/10.1172/jci196379

Vancouver

Chuang HC, Wang CW, Hsueh CH, Xiao YZ, Tsai CY, Hsu PM, et al. MAP4K2 suppresses antitumor immunity in a pancreatic cancer model by promoting Treg differentiation. Journal of Clinical Investigation. 2026;136(6). doi:10.1172/jci196379

BibTeX
@article{Chuang2026,
  author = {Chuang, Huai-Chia and Wang, Chia-Wen and Hsueh, Chia-Hsin and Xiao, Yu-Zhi and Tsai, Ching-Yi and Hsu, Pu-Ming and Tan, Evelyn L and Chiu, Hsien-Yi and Tan, Tse-Hua},
  title = {MAP4K2 suppresses antitumor immunity in a pancreatic cancer model by promoting Treg differentiation},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {6},
  doi = {10.1172/jci196379}
}
Kostenlos starten →